- Home
- FTHM vs KYNB Comparison
FTHM vs KYNB Comparison
Compare FTHM & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | KYNB |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 31.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | FTHM | KYNB |
|---|---|---|
| Price | $0.73 | $7.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 69.5K | 33.9K |
| Earning Date | 03-30-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $335,184,000.00 | N/A |
| Revenue This Year | $30.07 | N/A |
| Revenue Next Year | $14.66 | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.65 | $6.67 |
| 52 Week High | $3.37 | $9.58 |
Technical Indicators
Market Signals| Indicator | FTHM | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 32.57 | 45.13 |
| Support Level | N/A | $6.67 |
| Resistance Level | $1.49 | $7.65 |
| Average True Range (ATR) | 0.06 | 0.38 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 12.94 | 45.41 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.